medigraphic.com
ISSN 1561-302X (Print)

2015, Number 2

<< Back Next >>

Rev cubana med 2015; 54 (2)

Serum magnesium levels in oncologic patients treated with nimotuzumab

Bacallao MRA, Crombet RT, Dávalos IJM, Mañalich CR, Llerena FB, Gutiérrez GF

Language: Spanish
References: 28
Page: 139-150
PDF size: 143.06 Kb.


ABSTRACT

Introduction: some adverse effects have been reported with the use of monoclonal antibodies against Epidermal Growth Factor Receptor (EGFR), including hypomagnesaemia and hypocalcaemia. Nimotuzumab is a Cuban anti-EGFR antibody with a particular mechanism of action, so it is important to know if Nimotuzumab causes these adverse effects.
Objective: assess whether the administration of this drug causes hypomagnesemia and secondary hypocalcemia, like other anti-EGFR.
Methods: patients on this study came from the controlled clinical assay: Use of Monoclonal Antibody Nimotuzumab in Treatment of Patients with Squamous-Cell Carcinoma of the Head and Neck In Advance Stages. 12 patients were taken by simple random sampling from each group of treatment of clinical assay (total 24). Demographic and anthropometric variables were recorded and mensuration of calcium and magnesium were done from serum samples obtained during clinical assay and preserved at –86 °C. Information was processed using statistical package SPSS 15.0. Friedman test and Wilcoxon test were used to assess changes in Ca and Mg concentrations. Wilcoxon-Mann-Whitney test was used to compare the groups.
Results: both groups of subjects had similar characteristics. In the group of patients treated with nimotuzumab, Magnesium concentrations mean were 2.06, 2.17 and 2.11 mg/dL, at the beginning, after three weeks and at the end of treatment, respectively (p=0.72). There were not differences in Mg and Ca concentration changes along the study between groups (p= 0.07 y p= 0.86).
Conclusions: there are not evidences to establish that nimotuzumab causes hypomagnesaemia and secondary hypocalcaemia in treatment of 200 mg a week during six weeks.


REFERENCES

  1. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypo magnesemia. J Natl Cancer Inst. 2005;97:1221-4.

  2. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van Cutsem E. Magnesium wasting associated with epidermal-growth factor receptortargeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387-94.

  3. Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer. 2006;6:152-6.

  4. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney. J 2012;5(Suppl 1):i3-i14.

  5. Houillier P. Mechanisms and regulation of renal magnesium transport. Annual review of physiology. 2014;76:411-30.

  6. Ferre S, Hoenderop JG, Bindels RJ. Insight into renal Mg2+ transporters. Curr Opin Nephrol Hypertens. 2011;20:169-76.

  7. Geiger H, Wanner C. Magnesium in disease. Clin Kidney J. 2012;5(Suppl 1):i25-i38.

  8. Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260-7.

  9. Thebault S, Alexander RT, Groenestege WM, Hoenderop JG, Bindels RJ. EGF Increases TRPM6 Activity and Surface Expression. J Am Soc Nephrol. 2009;20:78-85.

  10. Quinn SJ, Thomsen AR, Pang JL, Kantham L, Bräuner-Osborne H, Pollak M, et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab. 2013;304(3):E310-E320.

  11. Rivera F, Vega-Villegas ME, López-Brea MF, Márquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncológica. 2008;47:9-19.

  12. Allan DG. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist. 2005;10:760-1.

  13. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646-54.

  14. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther. 2009;9(9):1199-206.

  15. Garrido G, Rabasa A, Gracia E. Binding properties of the anti-EGFR monoclonal antibody, Nimotuzumab, limit its interaction with the EGFR in renal and epidermal cells. AACR 100th Annual Meeting, 2009 (abstract 2763). [citado 26 Abr 2014]. Disponible en: http://www.ymbiosciences.com/upload_files/nimo_poster_AACR2009.pdf

  16. Tikhomirov I, Garrido G, Rabasa A, Pérez R. Differences in clinical safety profiles of Nimotuzumab and cetuximab, EGFR-targeting antibodies, as a consequence of divergent monovalent/bivalent binding profiles of these agents. Annals of Oncology. 2009;20(Suppl 3):iii32–iii35.

  17. Osorio Rodríguez M, Cruz Rivero T, del Castillo Bahi R, Roca Muchuli C, Azcue Bilbao M, Neninger Vinageras E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biology & Therapy. 2010;9:343-49.

  18. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.

  19. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes. 1985;9:147-53.

  20. Bushinsky DA, Monk RD. Electrolyte quintet: Calcium. Lancet. 1998;352:306.

  21. Van Cutsem E, Peeters M, Siena S. Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer. Ann Oncol. 2006;17:vi19–vi27 (O 027).

  22. Mateo C, Moreno E, Amour K. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997;3(1):71-81.

  23. Arteaga ME, Ledón N, Casacó A. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody Nimotuzumab. Cancer Biol Ther. 2007;6(9):1390-5.

  24. Akashi Y, Okamoto I, Iwasa T. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer. 2008;98:749-55.

  25. Talavera A, Friemann R, Gómez-Puerta S. Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation. Cancer Res. 2009;69:(14):5851-9.

  26. Vincenzi B, Santini D, Tonini G. Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. Expert Opin Pharmacother. 2008;9(8):1267-9.

  27. Wolf FI, Trapani V, Cittadini A, Maier JA. Hypomagnesaemia in oncologic patients: to treat or not to treat? Magnesium Research. 2009;22(1):5-9.

  28. Reddy BK, Vidyasagar M, Shenoy K. BIOMAb EGFRTM (Nimotuzumab/h-r3) in combination with standard of care in squamous cell carcinoma of head and neck (SCCHN). Int J Radiat Oncol Biol Phys. 2007;69(3):S450.




2020     |     www.medigraphic.com